Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
EHang to Report Second Quarter 2022 Unaudited Financial Results on Thursday, August 18, 2022
August 08, 2022 08:00 ET
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 08, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
EH216 Completes Demo Flight Tour in 4 Japanese Cities to Mark 1,000-Day Countdown of Expo 2025 Osaka, Kansai
July 22, 2022 08:38 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 22, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
July 21, 2022 07:00 ET
|
Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
July 19, 2022 08:00 ET
|
Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
EHang Announced Strategic Partnership with Agricultural Bank of China Guangzhou Branch with Indicative Facilities of RMB1 Billion for Long-Term Cooperation
June 28, 2022 08:11 ET
|
EHang Holdings Limited
GUANGZHOU, China, June 28, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET
|
Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
EHang Partners with Tianxingjian on Scenic Flight Project with EH216 AAVs at Aizhai Wonder Tourist Area in Jishou, Hunan, China
June 21, 2022 09:17 ET
|
EHang Holdings Limited
GUANGZHOU, China, June 21, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...